Bill Christiansen

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Cooley advised Asymchem, a Chinese-based contract development and manufacturing company serving the global pharmaceutical and biotech industry, on its definitive agreement to acquire Snapdragon Chemistry, a US-based chemical technology company. Partner Yiming Liu led the Cooley team.

As a result of the transaction, Asymchem will significantly expand its footprint in the US, offering customers a seamless path from preclinical process R&D through commercial current good manufacturing practice (cGMP) production. Snapdragon will operate as a stand-alone Asymchem division, and continue with its ongoing lab and manufacturing facility expansion for additional capacity to support larger, pilot-scale manufacturing in Waltham, Massachusetts.

"We believe continuous flow manufacturing is a revolutionary technology and represents the future of pharmaceutical production, not only generating advantages to process safety and cost, but also bringing tremendous environmental benefits," Hao Hong, chairman and CEO of Asymchem, said in a news release. "Asymchem has been deeply committed to flow chemistry technology development and its application expansion in the pharmaceutical industry for more than a decade. We are excited that this strategic acquisition will further strengthen our capabilities in continuous manufacturing, as well as broadening our service scope and client pool."

Cooley advised Shoreline Biosciences, a biotechnology company developing immunotherapies for cancer and other serious diseases, on its worldwide strategic collaboration with BeiGene to develop and commercialize a portfolio of natural killer-based cell therapeutics. Lawyers Charity Williams and Bin Wang led the Cooley team advising Shoreline.

Cooley advised GGV Capital on raising $2.52 billion across four funds, which will focus on tech startups and growth deals in the US and China. The closing represents the largest family of funds raised by GGV since its inception. Partner Jordan Silber led the Cooley team advising GGV.

Cooley advised Celularity, a clinical-stage biotechnology company developing off-the-shelf allogeneic therapies derived from the postpartum human placenta, on its agreement to become a public company by merging with GX Acquisition Corp., a special purpose acquisition company. Upon closing of the transaction, which is expected in Q2, GX will be renamed Celularity, and its common stock and warrants are anticipated to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” Yvan-Claude Pierre, Marc Recht, Kevin Cooper and Marianne Sarrazin led the Cooley team advising Celularity on the transaction.

Read more